Newbridge Financial Services Group’s Castle Biosciences CSTL Stock Holding History

Newbridge Financial Services Group’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$35.5K	Buy	+1,000	New	+$30.2K	﹤0.01%	555

Other funds holding CSTL

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Newbridge Financial Services Group's CSTL Position: Q3 2026 in Review

Newbridge Financial Services Group opened a new position in Castle Biosciences (CSTL) in Q3 2026: 1,000 shares worth $35.5K. The stake represents ﹤0.01% of the portfolio and ranks #555 among its holdings.

94 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

Newbridge Financial Services Group held 1,000 shares of Castle Biosciences worth $35.5K as of Q3 2026.
Castle Biosciences was a new Newbridge Financial Services Group position in Q3 2026.
Castle Biosciences made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q3 2026, its #555 holding.
94 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Newbridge Financial Services Group's 13F filing for Q3 2026, filed 15 Oct 2026.